Effective August 2, 2022, mdxhealth has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences. To help ensure a smooth transition for patients, continue to place orders for this test through the existing Exact Sciences portal until further notice. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the Oncotype DX GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the following press release. Questions? Email: gps@mdxhealth.com

 

Colon cancer is the third most prevalent cancer for both men and women in the United States. It’s also the second most common cause of cancer-related deaths1—yet no two colon cancer patients, or their treatment needs, are the same. Each patient has an individualized level of risk, making the choice of treatment different for everyone. Part of the treatment decision making process involves understanding the likelihood of the colon cancer returning and how a patient’s condition is managed after surgery.

The Oncotype DX Colon Recurrence Score® test is clinically validated to quantify the risk of recurrence of patients with anatomic stage II, MMR-P and stage III A/B colon cancers. The 12-gene genomic test (seven cancer-related genes and five reference genes) looks at the underlying biology of a patient’s tumor so patients can choose a treatment that fits their unique situation.